Drug intelligence / Profile preview

MV-SARS-CoV-2

Development stage: Preclinical
Lead developer: Merck
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

MV-SARS-CoV-2 is a preclinical vaccine candidate developed by Themis, which was acquired by MSD. This vaccine utilizes a measles virus vector platform to target SARS-CoV-2, aiming to provide protection against the virus.

Beyond the preview

Go deeper on MV-SARS-CoV-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MV-SARS-CoV-2.

Explore the full profile